Clinical Trial: Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07807722) titled 'Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC' on Aug. 21.

Brief Summary: Exploring the efficacy and safety of firmonertinib combined with anlotinib and platinum-based doublet chemotherapy as neoadjuvant therapy in patients with EGFR-mutant resectable NSCLC

Study Start Date: Sept. 21

Study Type: INTERVENTIONAL

Condition: NSCLC (Non-small Cell Lung Cancer) EGFR Neoadjuvant Therapy

Intervention: DRUG: Firmonertinib combined anlotinib and chemotehrapy

EGFR-TKI: Firmonertinib 80mg daily Antiangiogenic drugs: Anlotinib 8-12mg daily, D1-14 an...